Biofrontera Q3 revenue $7.0M, net loss $6.6M; closes Ameluz asset purchase

Biofrontera Inc.

2025-Q3 EPS reported -$1.67 revenue$24,605,000

Q3 2025 revenues $7.0M (down 22% YoY); 9-month revenues stable at $24.6M vs $24.8M.
Net loss $6.6M vs $5.7M in Q3 2024; Adjusted EBITDA -$6.0M vs -$4.6M.
Closed purchase of all U.S. assets for Ameluz and RhodoLED from Biofrontera AG; earnout reduced to 12-15% of net sales.
Divested Xepi antibiotic cream to Pelthos Pharmaceuticals for $3M closing plus up to $6M milestones.
Cash $3.4M at Sep 30; additional $2.5M received in Oct; runway extended by asset purchase and divestiture.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.